| 1 |
35289492 | Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series. | 2022 Mar 15 |
1 |
| 2 |
33405090 | Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. | 2021 Jun |
1 |
| 3 |
33549085 | Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change. | 2021 Feb 6 |
1 |
| 4 |
33978635 | Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo. | 2021 Jan-Dec |
3 |
| 5 |
34127699 | Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity. | 2021 Jun 14 |
4 |
| 6 |
31942645 | The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model. | 2020 Mar |
1 |
| 7 |
32181767 | [vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors]. | 2020 Mar 17 |
1 |
| 8 |
32504375 | Selumetinib: First Approval. | 2020 Jun |
3 |
| 9 |
32533336 | Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects. | 2020 Aug |
1 |
| 10 |
32629964 | The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma. | 2020 Jun 30 |
1 |
| 11 |
30317534 | Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. | 2019 Jun |
3 |
| 12 |
30579838 | Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models. | 2019 Feb |
1 |
| 13 |
30706361 | Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer. | 2019 Apr |
2 |
| 14 |
30771306 | SPRED2 deficiency elicits cardiac arrhythmias and premature death via impaired autophagy. | 2019 Apr |
1 |
| 15 |
31040916 | A novel anti-melanoma SRC-family kinase inhibitor. | 2019 Mar 19 |
2 |
| 16 |
31201369 | A DSTYK mutation activates ERK1/2 signaling to promote intraspinal dissemination in a case of solitary fibrous tumor/hemangiopericytoma. | 2019 Oct |
1 |
| 17 |
31285371 | ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer. | 2019 Oct 1 |
2 |
| 18 |
29670612 | N-Formyl Peptide Receptors Induce Radical Oxygen Production in Fibroblasts Derived From Systemic Sclerosis by Interacting With a Cleaved Form of Urokinase Receptor. | 2018 |
1 |
| 19 |
29719377 | Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells. | 2018 |
2 |
| 20 |
30172884 | Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation. | 2018 Dec |
2 |
| 21 |
30343534 | Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition. | 2018 Dec |
5 |
| 22 |
28424891 | A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. | 2017 Oct |
3 |
| 23 |
28620782 | Role of key genetic mutations on increasing migration of brain cancer cells through confinement. | 2017 Sep |
1 |
| 24 |
28791489 | Metalloprotease-dependent activation of EGFR modulates CD44+/CD24- populations in triple negative breast cancer cells through the MEK/ERK pathway. | 2017 Nov |
1 |
| 25 |
26802155 | Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. | 2016 Apr |
3 |
| 26 |
27422710 | Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. | 2016 Oct |
1 |
| 27 |
27438013 | Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway. | 2016 |
5 |
| 28 |
27713506 | PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness. | 2016 Oct 7 |
1 |
| 29 |
25498501 | The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244. | 2015 Jan 16 |
2 |
| 30 |
25933683 | Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. | 2015 Jul |
1 |
| 31 |
26250606 | Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer. | 2015 Nov |
3 |
| 32 |
26384399 | MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. | 2015 Dec |
1 |
| 33 |
26567773 | Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer. | 2015 Nov 16 |
3 |
| 34 |
24938872 | MEK inhibitor effective against proliferation in breast cancer cell. | 2014 Sep |
1 |
| 35 |
25130256 | Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. | 2014 Nov |
1 |
| 36 |
25199829 | RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. | 2014 Sep 11 |
1 |
| 37 |
22310287 | Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. | 2013 Jan 3 |
1 |
| 38 |
23320839 | MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. | 2013 Jan 15 |
1 |
| 39 |
23414467 | Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer. | 2013 Feb |
1 |
| 40 |
23602735 | Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways. | 2013 Oct |
2 |
| 41 |
22275507 | Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. | 2012 Mar 15 |
1 |
| 42 |
22573716 | Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. | 2012 Jul 1 |
1 |
| 43 |
22641227 | Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma. | 2012 Aug |
2 |
| 44 |
22765220 | Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. | 2012 Jul 5 |
1 |
| 45 |
22821509 | The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. | 2012 Nov |
1 |
| 46 |
23372439 | (18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. | 2012 May |
3 |
| 47 |
21118963 | MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. | 2011 Jan 15 |
1 |
| 48 |
21215703 | EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. | 2011 Jan 18 |
1 |
| 49 |
21447798 | Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. | 2011 Mar 29 |
1 |
| 50 |
21628402 | The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. | 2011 Jul 28 |
2 |